Giorgio Napoli, MD
Cardiovascular Disease · Upton, MANPI 1225398282
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,825 of the $2,700 with a category attached, or 67.6%. 14 manufacturers reported payments, led by Vertex at 34.3% of the total. Reporting peaked in 2021 at $1,198 and has fallen 77.9% since, to $265 in 2025.
Across 42 payments — averaging $64.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$925
- Vifor (international) Ltd.$900
- Boston Scientific$250
- Atricure, Inc.$172
- Johnson & Johnson$109
- E.r. Squibb & Sons, L.L.C.$67
- plus $277 from 8 others
What the payments were for
- Consulting fees$1,82568%
- Food & beverage$87532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 2 | $925 |
| Vifor (international) Ltd. | 2 | $900 |
| Boston Scientific | 12 | $250 |
| Atricure, Inc. | 6 | $172 |
| Johnson & Johnson | 4 | $109 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Edwards Lifesciences | 2 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $56 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $37 |
| Boehringer Ingelheim | 1 | $36 |
| Medtronic | 2 | $35 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
How this compares
$2,700 in reported general payments places this provider in the 60th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $28,219 |
| XareltoRivaroxaban | 19 | $14,231 |
| Metoprolol Succinate | 74 | $921 |
| Rosuvastatin Calcium | 29 | $892 |
| Atorvastatin Calcium | 72 | $727 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 54 | $711 |
| Pravastatin Sodium | 19 | $365 |
| Torsemide | 23 | $322 |
| Ezetimibe | 16 | $302 |
| Losartan Potassium | 40 | $284 |
| Furosemide | 62 | $190 |
| Amlodipine Besylate | 21 | $180 |
| Lisinopril | 27 | $145 |
| Nitroglycerin | 12 | $138 |
| Metoprolol Tartrate | 22 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $109 | $14,23119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Upton
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- Kevin CroceChestnut Hill$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.